Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you Phanthom!
Should Sticky that post.
-Best of Luck to All
Looks like Ovarian trial is now fully recruited and closed. They were waiting on the 50th patient for interim analysis. Looks like it completed ahead of the revised schedule (was set for end of QTR2 with data at year end). Hopefully they can tighten the estimates on data. Maybe around Aug???
https://clinicaltrials.gov/ct2/show/NCT02978222?term=tpiv&rank=3
-Best of Luck to All
I agree 100%.
I would rather they never hit the "merge" button on that. Marker is in a unique position... They have a bank full of cash, and no debt.... and it would be a pure waste of money to merge with them. If they proceed with merging, it sends a terrible signal that they have nothing better to spend the money on.
“market will wake up and catch on, and the price will skyrocket”
Agree 100%... patiently waiting for the next leg up. I can’t understand why we are not closer to $20 at this Point.
Good to see you Blu!
Hope all is well with you and your family!
Epicare.... great summary!
Everything looks good... but the stock price!
Hopefully Soon, the market cap will be reasonable.
Curious on updates for tonight’s presentation. If anyone has links or updates, please provide.
Thanks!
1014 Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy
Hematology Disease Topics & Pathways:
Biological, multiple myeloma, viral, Diseases, Therapies, immunotherapy, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies
Monday, December 3, 2018: 7:30 PM
1014 Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy
Hematology Disease Topics & Pathways:
Biological, multiple myeloma, viral, Diseases, Therapies, immunotherapy, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies
Monday, December 3, 2018: 7:30 PM
To date we have infused 18 patients with at least 2 infusions, 2 weeks apart of doses ranging from 0.5 to 2x107/m2. These patients had received a median of 4 lines of prior therapy including high dose chemotherapy with autologous stem cell rescue. Ten patients were refractory to their latest therapy and had active MM, while 8 were in remission at the time of infusion. At the 6 week evaluation period, of the 10 patients receiving multiTAA-specific T cells to treat active disease, 1 had a complete remission (CR) by the international myeloma working group (IMWG) response criteria, 1 had a partial remission (PR) and 8 others had stable disease (SD). Seven of these 10 patients were infused more than 1 year ago. Although 2 of the 7 subsequently had disease progression, the remaining 5 continue to respond, with sustained CR (1), PR (2) or SD (2). Of the 8 patients in CR at the time of T cell infusion, all remained in CR at the week 6 disease assessment and of the 6 evaluable patients who are >1 year post T cells, only one patient has relapsed, at 7 months after T cell infusion.
These clinical responses correlated with the emergence and persistence (>6 months) of “line-exclusive” tumor-reactive T cells in patient peripheral blood, as assessed by longitudinal tracking of infused T cell clones using TCR deep sequencing. These infused product-derived T cells were detected in both peripheral blood (mean 0.43% ±SD of 0.3 of the total repertoire) and the marrow (mean 0.61%±0.24% of total repertoire). The expansion of product-derived T cell clones was higher among patients with active MM than in patients treated in remission (active: 0.60±0.39%, remission: 0.2±0.08%, p=0.048).
Notably, no patient, including the complete responder, had infusion-related systemic- or neuro-toxicity. Thus, autologous multiTAA-targeted T cells directed to PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin can be safely administered to patients with MM, in whom they can subsequently be detected long-term in peripheral blood and marrow, and where they produce sustained tumor responses including CR. It will be of interest to discover whether larger or more frequent doses of these T cells can produce further benefit with maintained safety.
https://ash.confex.com/ash/2018/webprogram/Paper113118.html
2693 Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens
Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways:
Biological, ALL, Leukemia, Diseases, Therapies, Pediatric, Technology and Procedures, cell expansion, Study Population, immunotherapy, Lymphoid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Thus far we have treated 8 high risk ALL patients with donor derived TAA T cells post-transplant to prevent disease relapse (Table 1). Infusions were well tolerated with no dose-limiting toxicity, GVHD, CRS or other adverse events. Two patients were not evaluable per study criteria as they received >0.5mg/kg of steroids within 4 weeks of infusion and were replaced. Five of the 6 remaining patients infused remain in CR a median of 11.2 months post-infusion (range 9-22 months). We detected the expansion of tumor-reactive T cells in patient peripheral blood post-infusion against both targeted (WT1, Survivin, PRAME) and non-targeted antigens (SSX2, MAGE-A4, -A1, -A2B, -C1, MART1, AFP and NYESO1) reflecting epitope and antigen spreading. The single patient who relapsed showed no evidence of tumor-directed T cell expansion despite receiving 3 additional infusions at 4 week intervals.
Conclusion: In summary, infusion of donor multi-TAA-specific T cells to patients with ALL post allogeneic HSCT is feasible, safe and as evidenced by expansion and antigen spreading in patients, may contribute to disease control. This strategy may present a promising addition to current immunotherapeutic approaches for prophylaxis for leukemic relapse in HSCT recipients.
https://ash.confex.com/ash/2018/webprogram/Paper115465.html
1685 Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells
Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways:
Diseases, Biological, Lymphoma (any), Therapies, immunotherapy, Lymphoid Malignancies, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM
We have treated 33 patients: 13 with HL, 17 with aggressive NHL (diffuse large B-cell, mantle cell, or T cell lymphomas) and 3 with indolent NHLs (FL and marginal zone lymphoma). Patients received 0.5-2x107 multiTAA-T cells/m2. Of 18 patients who were infused as adjuvant therapy all but 2 remain in remission (range 3-42 months post-infusion). Fifteen patients have received multiTAA-specific T cells to treat active disease, all of whom had failed a median of 4 lines of prior therapy. Of these, 5 had transient disease stabilization followed by disease progression, 4 have ongoing stable disease, 3-18 months post-multiTAA-specific T cells while the remaining 6 (3 with HL and 3 with DLBCL) have all had complete and durable responses ( 4 to 41 months), as assessed by PET imaging. These clinical responses correlated with the detection of tumor-reactive T cells in patient peripheral blood post-infusion directed against both targeted antigens as well as non-targeted TAAs including MAGEA2B and MAGE C1, indicating induction of antigen/epitope spreading. Notably, no patient, including the complete responders, had infusion-related systemic- or neuro-toxicity. Thus, infusion of autologous multiTAA-targeted T cells directed to PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin has been safe and provided durable clinical benefit to patients with lymphomas.
https://ash.confex.com/ash/2018/webprogram/Paper113140.html
ASH presentation
The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
--Three abstracts accepted, including oral presentation on multiple myeloma clinical data--
HOUSTON, Nov. 27, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018). The studies describe results achieved using multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan Vera, and exclusively licensed to Marker.
https://finance.yahoo.com/news/center-cell-gene-therapy-baylor-213200120.html
Marker Therapeutics (MRKR) gets a new Buy rating and $16 price target at Nomura this morning. Nomura's analyst 'believes the company's MultiTAA platform, which selects for and expands patient tumor-specific T cells by directly presenting a blend of tumor-associated antigens and cytokines in vitro, is "amenable to rapid approval." Further, Marker is trading at a discount to immunotherapy peers despite offering a "strong" de-risking data flow that will likely result in share upside over the next 12 months'
https://seekingalpha.com/instablog/498952-bret-jensen/5239075-4-notable-thanksgiving-analyst-calls
Please keep us posted.
Would be nice to see Peter add at these levels to show that we are ridiculously undervalued.
Yes.. agree... except not “great” which is what we all want... kind of middle of the road... good, some green shoots, but nothing tremendous... which is why we are going sideways with stock price ... Management really needs to step up and communicate the value of the combined company... build it, and they will come, is not enough,
I have taken advantage of down days and added to my position.
- Good luck to All
I believe we are talking about same study... ended at the 27 patients and not continuing to second half... some good results, but more time is needed. Not new news (so maybe we are talking different)... I have been adding at these low levels, market cap is beyond ridiculous.
- 7 patients or 26% exhibited stable disease. Interestingly, several patients had pretty durable disease stabilization with 22% of patients being on the study beyond 24 weeks.
- median overall survival was 21 months which is much higher than we would expect in this patient population. Because this was a single institution study, we had the opportunity to look at subsequent therapies that the patient received and saw significant responses even to standard chemotherapy, often to drugs that patients had already received.
- Many of the patients went on to receive several lines of therapy and had durable benefit from each of these therapy lines. These findings, while from a relatively small cohort, highlight that cancer immunotherapies can make a durable impact on tumor biology even without an objective response and may affect responses to subsequent treatments.
- We are in the process of performing translational studies to delineate whether the responses to the vaccine or the vaccine-immunotherapy combination were predictive of clinical benefit during the trial and perhaps, predictive of the benefit to subsequent chemotherapies. it would also be prudent to evaluate the vaccine in combination with chemotherapy to see if responses to chemotherapy, or perhaps, the durability of chemotherapy benefit could be improved with this combination.
I couldn’t find the original release, but below is where I am grabbing the quotes from. Nothing new, but interesting to see longer term analysis.
http://www.cancernetwork.com/ovarian-cancer-research-symposium/target-folate-receptor-alpha-ovarian-cancer
I am not sure when the long term results will be in. They are still tracking a subset of the original 27.
We already know that the trial will not continue to the second half. They are going to most likely try other combinations to see what really works with TPIV200.
Seems like there are nuggets of good news, just need them to package it up for us. Right now, I would say that more time is needed for analysis, but sample size, in the end, might be too small to draw massive buying of stock... which we are all waiting for. Odd that we are barely pricing in Marker right now... let alone legacy TPIV assets.
Just my opinion.
Eagle1... great job on the updates. Looks great!
Have been traveling a bit lately, so sorry for the late reply.
Thanks for all the hard work!!!
Flyingj... just guessing, but I believe the reference is to the material sent with proxy voting.
Form DEFM14A TAPIMMUNE INC.
BY 10K Wizard
— 2:56 PM ET 09/14/2018
http://archive.fast-edgar.com/20180914/AAA2C22CZZ22G9ZZ2R9K2ZZHSLLKCB22Z2A2
Filed on: September 14, 2018
That was most likely a block trade between institutional holders. Happens all the time. (Not with MRKR, market in general)
They are prearranged sales/buys, at or near market price.. so large blocks can change hands without moving the stock price.
Could be one of Phantom’s over subscribers adding.
Thanks for the post! nice article.
Might get a bump from the Baker Bros followers and "Follow the Money" crowd.
Seems unanimous... extremely undervalued..
-Best of Luck to All
Baker Bros... interesting
Thanks Eagle!!! Appreciate all the work you do as moderator!
Future looks great for Marker.
Moderators: Instructions to change board to MRKR
How do I get a board name/symbol changed?
If you are the board's Moderator or an Assistant you can go to the Manage page and click Board Name/Ticker Change and fill in the requested information. These go into a queue that are reviewed by site Admins throughout the day.
http://ihwiki.advfn.com/index.php?title=Most_Frequently_Asked_Questions#How_do_I_get_a_board_name.2Fsymbol_changed.3F
It would be a shame to migrate over to new board and lose tremendous amount of DD here
Absolutely
Thin trading so far... been up to $10.25 on very light volume
Seaking Alpha article... good read so far
https://seekingalpha.com/article/4212367-marker-therapeutics-safer-potentially-effective-car-t-alternative
Marker Therapeutics: A new start
I think that the only way to view the newly merged company is as a new company. Given the fervor for biotech IPO's this year, I was honestly a little surprised that Marker didn’t go it alone and do an IPO, but clearly they saw value in the combination of the two organizations. I have no doubt that part of that rationale is that both companies were similar in their goal which goes back to the beginning of this article regarding stimulating the immune system to safely eliminate cancer. CAR-T therapies do a fair job of eliminating cancer cells but safely? Not so much. I also believe that the leadership of the organization under Dr. Hoang, coupled with the outstanding scientific aptitude brought from Marker will be a fantastic combination. If you are considering this company, you SHOULD DEFINITELY spend an hour listening to Dr. Ann Leen's YouTube data presentation, and especially during the Q&A from 1:03-1:19. The rigor and rationale with which they've conducted Marker's studies so far is nothing short of impressive. The advisory board is no slouch either and includes multiple experts in cell therapies including recent Nobel Prize recipient Jim Allison.
When you look the Marker’s intelligent approach and data set of their technology in over 60 patients, and you overlay that with companies like Kite and Juno who won approved therapies with relatively small numbers of patients, and were then bought out for $11.9B and $9B respectively. The company should quickly become multiples of its current value.
Looking at other recent IPO examples, in particular Allogene (ALLO) which recently IPO'd with a value of over $3B, Marker would appear highly undervalued. Allogene is another CAR-T developer, but with a dataset that is aruguably less mature than Marker's and with a safety profile that is consistent with other CAR-T's. UCART19 had been previously on FDA hold due to patient deaths. In their summer 2018 data release with only 6 children in R/R B cell ALL, the data were interesting, but not fantastic. All patients experienced CRS, and other SAE's were observed. While 5 out of 6 experienced a CR, they all underwent allo-HST post-therapy and only 2 survived greater than 6 months post-HST. Allogenes product is differentiated from other CAR-T's, however, in that any donor's T cells can be used as opposed to a specific patient's. This is why many have referred to Allogene's therapy as an "off-the-shelf" CAR-T. It will still be far more expensive to produce than MultiTAA T cells.
Another recent notable IPO, was for Arvinas (ARVN). Arvinas currently has a $500M market cap for a cancer company that has not even entered clinical trials. Again, this is a pre-IND company with an interesting PROTAC cancer treatment paradigm. PROTAC therapies are designed to link proteins intended for destruction via the ubiquitination/proteasome system. Unlike Takeda's (OTCPK:TKPYY) Velcade, which inhibits the proteasome, PROTAC therapies are hoped to use the proteasome in order to "drug the undruggable" by selectively removing unwanted receptors or cell signaling mediators. While a fascinating therapy, they have never put medicine into a human and are not expected to treat their first patient until sometime in 2019.
I feel that if Marker had IPO'd, they probably could have commanded a market value closer to $2B. Fully diluted, that would give them a share price of around $29.41. I think that the time between the announcement of the merger and the late execution of the merger created a little apathy for TapImmune's share price. But with the successful completion of the merger in the rear view mirror, I believe that the merged company will appreciate in value quickly. I think that the rationale for the merger with TapImmune was built on their common interest in antigen-driven immune stimulation. Their approach was the only difference here, with TapImmune performing vaccinations with antigens intended to build an immune response and Marker doing the same ex vivo in culture. There may be crossover opportunities.
While it's difficult to rationalize a more traditional valuation for the company at this point, if a MultiTAA T cell product were to eventually hit the market at half of the price of the CAR-T therapies, the post Allo-HST AML market alone would probably represent over $1.8B annually. The lymphoma market in active disease could probably be 2x that, but I think the real value generator for Marker could be as maintenance therapy. Here, as an adjuvant maintenance therapy, in multiple cancer indications (including hematological malignancies and solid tumors) Marker could yield unprecedented revenues and would have no competition from CAR-T or any of the other traditional therapies, because all of them have adverse event profiles that would contraindicate their use for this. A cogent discussion around future run-rate revenue simply cannot be had at this point.
Agree 100%
Looking forward to the day that we trade at sensible market cap levels... we have been trading at a massive discount for too long...
Hopefully they have a media blitz campaign firing on a cylinders in the next few months.
Data will be coming soon... many many irons in the fire...
Lots to look forward to!
-Best of Luck to All
Fidelity swapped out to MRKR
Current Bid-Ask.... $8.30 x $8.35
Hopefully iHub rolls over too
-Best of luck to All
Upcoming Marker presentations
http://www.prnewswire.com/news-releases/marker-to-present-at-two-upcoming-cellular-therapy-conferences-300733434.html
PDA Cell and Gene Therapy Conference:
Presentation Title: Moving Beyond CAR-T: Non-Engineered Multi-Antigen Specific T Cells Can Drive Significant Therapeutic Benefit for Patients with Lymphoma, Myeloma, and AML
Date: Tuesday, October 23, 2018
Location: Hyatt Regency Bethesda; Bethesda, MD
Time: 4:00pm (ET): Presentation
5:00pm (ET): Discussion Panel
Panel Title: Future of Cellular Therapy - The "Living Drug"
Date: Thursday, October 25, 2018
Location: Mintz Levin Offices, New York, NY
Time: 5:30pm (ET)
https://markertherapeutics.com/pipeline/
Impressive to see it all on one chart!
TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing
http://www.prnewswire.com/news-releases/tapimmune-and-marker-therapeutics-announce-successful-closing-of-previously-announced-merger-and-financing-300732824.html
Ringing the closing bell
President & Chief Executive Officer Peter L. Hoang, accompanied by the senior management team and Board of Directors, will ring the Nasdaq Closing Bell to mark the end of trading for today, October 17th.
The ceremony, which will take place between 3:45 p.m. and 4:15 p.m. Eastern Time, will stream live online at https://new.livestream.com/nasdaq/live.
Excellent News!!! Now, let’s get that next leg-up started!
It makes zero sense to me, that we are trading less than 300million market cap... so much upside just to get to sensible levels.
-Best of Luck to All
The 2018 Nobel Prize in Physiology or Medicine was awarded on Monday to James P. Allison of the United States and Tasuku Honjo of Japan for their work on unleashing the immune system’s ability to attack cancer, a breakthrough in developing new cancer treatments.
https://www.nytimes.com/2018/10/01/health/nobel-prize-medicine.html
https://tapimmune.com/2018/05/tapimmune-expands-scientific-advisory-board-with-cancer-immunotherapy-pioneers-james-p-allison-ph-d-and-padmanee-sharma-m-d-ph-d-from-the-md-anderson-cancer-center/
FYI...mailed proxy materials arrived today for one of my accounts..
as expected, you can vote online instead of mailing it back.
Looking forward to finally starting the next Leg up!
There is some great detail in the proxy more than supporting your share price estimates. (and my estimates are in the same area as yours)
If true, that many are simply not reading the details, then I would also agree with your previous statement that is seems like institutions have been accumulating... high volume and large blocks have been tossed around abit.
Still really surprised that our market cap is so low given all of the assets associated with the deal. One day, the market will wake up.
-Best of Luck
on a side note, I cant believe I followed that one trial(for so long) and it was not a TPIV/Mayo combo... too funny
Surprised we have not started the next leg up yet. There is zero dollars baked into the share price for Marker assets.
From Proxy
based on comparable companies analysis (provided in the release), the combined company is worth between $805million to $915Million... we are a fraction of that today.
Comparable Companies Analyses
TapImmune. Nomura performed a comparable company analysis with respect to TapImmune. Nomura reviewed and compared TapImmune to certain publicly traded companies that, similar to TapImmune, are pre-clinical Phase III stage oncology firms focused on developing treatments for various forms of cancer. Nomura used publicly available information and current and historical financial information for each such comparable company in its analysis. The companies selected were as follows:
• Aduro Biotech
• Immune Genocea
• Advaxis
In each case, these companies were selected on the basis of their financial and operating metrics and characteristics, including products in pre-clinical and clinical trials, risk profile, size and type of operations. Nomura calculated the enterprise values of each comparable company as of the close of market on May 11, 2018 and derived an implied equity valuation of TapImmune based on the mean and median enterprise values of such companies, which valuation assumed that TapImmune had a cash balance of? $5.1 million based on TapImmune’s public filings as of May 11, 2018. This analysis indicated the following approximate implied equity value reference range for TapImmune:
Approximate Implied
Equity Value Reference Range
$65 to $165
(in US$ millions)
Marker . Nomura performed a comparable company analysis with respect to Marker. Nomura reviewed and compared Marker to certain publicly traded companies that, similar to Marker, are Phase I to Phase II stage oncology firms focused on developing treatments for various forms of cancer. Nomura used publicly available information and current and historical financial information for each such comparable company in its analysis. The companies selected were as follows:
• Atara Biotherapeutics
• Iovance Biotherapeutics
• Adaptimmune Therapeutics
• Cellectis
• Ziopharm Oncology
• Bellicum Pharmaceuticals
• Celyad
• Unum Therapeutics
67
TABLE OF CONTENTS
In each case, these companies were selected on the basis of their financial and operating metrics and characteristics, including products in clinical trials, risk profile, size and type of operations. Nomura calculated the enterprise values of each comparable company as of the close of market on May 11, 2018 and derived an implied equity valuation of Marker based on the mean and median enterprise values of such companies. This analysis indicated the following approximate implied equity value reference range for Marker:
Approximate Implied
Equity Value Reference Range
$740 to $815
(in US$ millions)
Recruitment Status : Completed
https://clinicaltrials.gov/ct2/show/NCT01606241?id=NCT01606241&rank=1
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
TPIV keeps moving along nicely!
-Best of luck to all
Absolutely.... Lots of risk taken off the table... should see some decent upside from here.
-Best of Luck
Form DEFM14A TAPIMMUNE INC.
BY 10K Wizard
— 2:56 PM ET 09/14/2018
http://archive.fast-edgar.com/20180914/AAA2C22CZZ22G9ZZ2R9K2ZZHSLLKCB22Z2A2
Filed on: September 14, 2018
You are cordially invited to attend the 2018 annual meeting of stockholders, or the 2018 Annual Meeting, of TapImmune Inc., a Nevada corporation, which we refer to as TapImmune, which will be held at 9:00 a.m., local time, on October 16, 2018, at the Hyatt Regency Jacksonville Riverfront, 225 East Coastline Drive, Jacksonville, Florida 32202,
Looks like the next leg is starting... good follow through from Friday's volume.
Would be nice to see a close near HOD.
Lets test 13's soon!!!
-Best of Luck to All